Signaturefd, LLC Chemo Centryx, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 08, 2022	BUY	$22.17 - $51.8 $22 - $51	1 Added 1.41%	72 $4,000
Q2 2022 Aug 10, 2022	SELL	$15.36 - $27.51 $430 - $770	-28 Reduced 28.28%	71 $2,000
Q1 2022 May 02, 2022	SELL	$22.22 - $39.12 $377 - $665	-17 Reduced 14.66%	99 $2,000
Q4 2021 Jan 25, 2022	BUY	$18.38 - $40.5 $827 - $1,822	45 Added 63.38%	116 $4,000
Q3 2021 Oct 28, 2021	BUY	$13.18 - $19.83 $421 - $634	32 Added 82.05%	71 $1,000
Q3 2020 Nov 03, 2020	SELL	$46.35 - $61.69 $1,251 - $1,665	-27 Reduced 40.91%	39 $2,000
Q2 2020 Jul 30, 2020	BUY	$38.58 - $65.07 $1,041 - $1,756	27 Added 69.23%	66 $4,000
Q1 2020 Apr 23, 2020	BUY	$32.73 - $50.78 $1,276 - $1,980	39 New	39 $2,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.